Protein Kinase C, Tumor Promotors, and Synthetic Receptors
Previous   Next

  • Matthew D. Marsden; Xiaomeng Wu; Sara Mottahedan; Brian Loy; Adam J. Schrier; Brian A. DeChristopher; Akira J. Shimizu; Clayton T. Hardman; Stephen Ho; Christina M. Ramirez; Paul A. Wender; Jerome A. Zack; “Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents”. Virology, 2018, 520, 83-93. Abstract, Full Text, PDF.
  • Hao Yang, Daryl Staveness, Steven M. Ryckbosch, Alison D. Axtman, Brian A. Loy, Alexander B. Barnes, Vijay S. Pande, Jacob Schaefer, Paul A. Wender, Lynette Cegelski, “REDOR NMR Reveals Multiple Conformers for a Protein Kinase C Ligand in a Membrane Environment”. ACS Central Science, 2018, 4(1), 89-96. Abstract, Full Text, PDF.
  • Paul A. Wender, Clayton T. Hardman, Stephen Ho, Matthew S. Jeffreys, Ryan V. Quiroz, Steven M. Ryckbosch, Akira J. Shimizu, Jack L. Sloane, Matthew C. Stevens, Jana K. Maclaren, "Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV", Science, 2017, 358, 218-223. Abstract, Full Text, PDF.
  • Brice Albert, Austin Niu, Rashmi Ramani, Robert M. Williams, Garland R. Marshall, Paul A. Wender, Lee Ratner, Alexander B. Barnes, George B. Kyei, "Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analoges display remarkable potency to activate latent HIV without global T-cell activation", Scientific Reports - Nature, August 7, 2017, 7:7456. Full Text, PDF.
  • Matthew D. Marsden, Brian A. Loy, Xiaomeng Wu, Christina M. Ramirez, Adam J. Schrier, Danielle Murray, Akira Shimizu, Steven M. Ryckbosch, Katherine E. Near, Tae-Wook Chun, Paul A. Wender, Jerome A. Zack, "In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication", PLoS Pathogens, September 21, 2017. Full Text, PDF.
  • Tapan K. Khan, Paul A. Wender, Daniel L. Alkon; "Bryostatin and its synthetic analog rescue dermal fibroblasts from stress and contribute to survival and rejuvenation of human skin equivalents"; J. Cellular Physiology, 2017, Abstract, PDF.
  • Steven M. Ryckbosch, Paul A. Wender, Vijay S. Pande, "Molecular Dynamics Simulations Reveal Ligand-controlled Positioning of a Peripheral Protein Complex in Membranes", Nature Comm.., 2017,8, 6.  Abstract, PDF
  • Rana Abdelnabi, Daryl Staveness, Katherine E. Near, Paul A. Wender, Leen Delang, Johan Neyts, Pieter Leyssen, "Comparative analysis of salicylate-based bryostatin analogs with or without modification at position C26 confirms that the inhibitory effect on chikungunya virus replication also involves a non-PKC-dependent mechanism", Biochemical Pharmacology., 2016, 120, 15-21.  Text, PDF.
  • Stang, Stacey L.; Lopez-Campistrous, Ana; Song, Xiaohua; Dower, Nancy A.; Blumberg, Peter M.; Wender, Paul A.; Stone, Jim “ A Pro-apoptotic Signaling Pathway involving RasGRP, Erk and Bim in B Cells” Experimental Hematology, 2009, 37, 122-134. Abstract.
  • Shaha, S.P.; Tomic, J.; Shi, Y.; Pham, T.; Mero, P.; White, D.; He, L.; Baryza, J.L.; Wender, P.A.; Booth, J.W.; Spaner, D.E.; "Prolonging Microtubule Dysruption Enhances the Immunogenicity of Chronic Lymphocytic Leukemia Cells", Clinical & Experimental Immunolocy, 2009, 158, 186-198. Abstract, PDF.
  • Tapan Kumar Khan; Thomas J Nelson; Vishal A Verma; Paul A Wender; Daniel L Alkon: “A Cellular Model of Alzheimer’s Disease Therapeutic Efficacy: PKC Activation Reverses A-beta induced biomarker Abnormality on Cultured Fibroblasts” Neurobiology of Disease 2009, 34(2), 332-339.Abstract, PDF.
  • Statsuk, Alexander V.; Bai, Ruoli; Baryza, Jeremy L.; Verma, Vishal A.; Hamel, Ernest; Wender, Paul A.; Kozmin, Sergey A. "Actin is the primary cellular receptor of bistramide A" Nature Chemical Biology, 2005, 1, 383-388. PDF, Supporting Information
  • Hammond, C.; Shi, Y. H.; Mena, J.; Tomic, J.; Cervi, D.; He, L. W.; Millar, A. E.; DeBenedette, M.; Schuh, A. C.; Baryza, J. L.; et. al. "Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-activated Chronic Lymphocytic Leukemia Cells" J. Immunotherapy 2005, 28, 28-39. Abstract, PDF,.
  • Stone, J. C.; Stang, S. L.; Zheng, Y.; Dower, N. A.; Brenner, S. E.; Baryza, J. L.; Wender, P. A. "Synthetic Bryostatin Analogues Activate the RasGRP1 Signaling Pathway" J. Med. Chem. 2004, 47, 6638-6644. Abstract, PDF.
  • Baryza, J. L.; Brenner, S. E.; Craske, M. L.; Meyer, T.; Wender, P. A. "Simplified Analogs of Bryostatin with Anticancer Activity Display Greater Potency for Translocation of PKC delta-GFP" Chem. Bio. 2004, 11, 1261-1267.
  • Shindo, M.; Irie, K.; Nakahara, A,; Ohigashi, H,; Konishi, H.; Kikkawa, U.; Fukuda, H.; Wender, P. A. "Toward the Identification of Selective Modulators of Protein Kinase C (PKC) Isozymes: Establishment of A Binding Assay for PKC Isozymes Using Synthetic C1 Peptide Receptors and Identification of the Critical Residues Involved in the Phorbol Ester Binding" Bioorg. Med. Chem. 2001, 9, 2073-2081. Abstract
  • Tanaka M, Irie K, Nakagawa Y, Nakamura Y, Ohigashi H, Wender, P. A."The C4 Hydroxyl Group of Phorbol Esters is not Necessary for Protein Kinase C Binding" Bioorg. Med. Chem. Lett. 2001, 11, 719-722. Abstract
  • Nakagawa, Y.; Irie, K.; Ohigashi, H.; Hayashi, H.; Wender, P. A."Synthesis and PKC Isozyme Surrogate Binding of indothiolactam-V, A New Thioamide Analogue of Tumor Promoting indolactam-V" Bioorg. Med. Chem. Lett. 2000, 10, 2087-2090. Abstract
  • Wender, P. A.; Hinkle K. W. "Synthesis and Biological Evaluation of A New Class of Bryostatin Analogues: the Role of the C20 Substituent in Protein Kinase C Binding" Tetrahedon Lett. 2000, 41, 6725-6729. Abstract
  • Fukuda, H,; Irie, K,; Nakahara, A.; Ohigashi, H.; Wender, P. A. "Solid-Phase Synthesis, Mass Spectrometric Analysis of the Zinc-Folding, and Phorbol Ester-Binding Studies of the 116-Mer Peptide Containing the Tandem Cysteine-Rich C1 Domains of Protein Kinase C Gamma" Bioorg. Med. Chem. 1999, 7, 1213-1221.
  • Wender, P. A.; Kirschberg, T. A.; Williams, P. D.; Bastiaans, H. M. M.; Irie, K. "A New Class of Simplified Phorbol Ester Analogues: Synthesis and Binding To PKC and Eta PKC-C1b (Eta PKC-Cpd2)" Org. Lett. 1999, 1, 1009-1012. Abstract, PDF, Supporting Information,
  • Wender, P. A.; Koehler, M. F. T.; Wright, D. L.; Irie, K. "Mapping Phorbol Ester Binding Domains of Protein Kinase C (PKC): the Design, Synthesis and Biological Activity of Novel Phorbol Ester Dimers" Synthesis 1999, 1401-1406.
  • Irie, K.; Oie, K.; Nakahara, A.; Yanai, Y.; Ohigashi, H.; Fukuda, H.; Wender, P. A. "Synthesis and Phorbol Ester Binding of the Zinc-finger Like Sequences of All Protein Kinase C Isozymes, In Peptide Science 1998, M. Kondo, Ed.: Protein Research Foundation, Osaka , 65-68, 1999.
  • Wender, P. A.; Lippa, B.; Park, C. M.; Irie, K.; Nakahara, A.; Ohigashi, H. "Selective Binding of Bryostatin Analogues To the Cysteine Rich Domains of Protein Kinase C Isozymes" Bioorg. Med. Chem. Lett. 1999, 9, 1687-1690.
  • Fukuda, H.; Irie, K.; Nakahara, A.; Oie, K.; Ohigashi, H.; Wender, P. A. "Synthesis and Binding Studies of the 116-Mer Peptide Containing the Double Cysteine-Rich Motifs of Protein Kinase C Gamma" Tetrahedon Lett. 1998, 39, 7943-7946.
  • Wender, P. A.; Martincantalejo, Y.; Carpenter, A. J., Chiu, A.; Debrabander, J.; Harran, P. G.; Jimenez, J. M.; Koehler, M. F. T; Lippa, B."The Chemistry-Medicine Continuum: Synthetic, Computer, Spectroscopic and Biological Studies on New Chemotherapeutic Leads" Pure Appl. Chem.1998, 70, 539-546.
  • Irie, K.; Oie, K.; Nakahara, A.; Yanai, Y.; Ohigashi, H.; Wender, P. A.; Fukuda, H.; Konishi, H.; Kikkawa, U."Molecular Basis for Protein Kinase C Isozyme-Selective Binding: the Synthesis, Folding, and Phorbol Ester Binding of the Cysteine-Rich Domains of All Protein Kinase C Isozymes" J. Am. Chem. Soc. 1998, 120, 9159-9167. Abstract, PDF, Supporting Information,
  • Wender, P. A.; Debrabander, J; Harran P. G.; Jimenez J. M.; Koehler M. F. T.; Lippa, B; Park, C. M.; Siedenbiedel, C.; Pettit, G. R. "The Design, Computer Modeling, Solution Structure, and Biological Evaluation of Synthetic Analogs of Bryostatin 1" Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 6624-6629. Abstract, PDF,
  • Irie, K.;Yanai, Y.; Ohigashi, H.; Wender, P. A. "Synthesis and Characterization of Model Peptides Incorporating the Phorbol Ester-binding Domain of Protein Kinase C," Peptide Chemistry 1996: C. Kitada (Ed.), Protein Research Foundation, Osaka, 209, 1997.
  • Yanai, Y.; Irie, K.; Ohigashi, H.; Wender, P. A. "Synthesis and Characterization of the First Cysteine-Rich Domain of Novel Protein Kinase C"Bioorg. Med. Chem. Lett. 1997, 7, 117-122.
  • Irie, K.; Yanai, Y.; Oie, K.; Ohigashi, H.; Wender, P. A. "Protein Kinase C Regulatory Domain Surrogate Peptides: Effects of Metal Ions on Folding, Phorbol Ester-Binding, and Selectivity" Bioorg. Med. Chem. Lett. 1997, 7, 965-970.
  • Irie, K.; Yanaim, Y.; Oie, K.; Ishizawa, J.; Nakagawa, Y.; Ohigashi, H.; Wender, P. A.; Kikkawa, U. "Comparison of Chemical Characteristics of the First and the Second Cysteine-Rich Domains of Protein Kinase C Gamma" Bioorg. Med. Chem. 1997, 5, 1725-1737.
  • Irie, K.; Isaka, T.; Iwata, Y.; Yanai, Y.; Nakamura, Y.; Koizumi, F.; Ohigashi, H.; Wender, P. A.; Satomi, Y.; Nishino, H. "Synthesis and Biological Activities of New Conformationally Restricted Analogues of (-)-Indolactam-V: Elucidation of the Biologically Active Conformation of the Tumor-Promoting Teleocidins" J. Am. Chem. Soc. 1996, 118, 10733-10743. Abstract, PDF, Supporting Information
  • Irie, K.; Yanai, Y.; Ohigashi, H.; Wender, P. A.; Miller, B. L."Synthesis and Characterization of the Second Cysteine-Rich Region of Mouse Skin PKC Eta" Bioorg. Med. Chem. Lett. 1996, 6, 353-356.
  • Irie, K.; Ishii, T.; Ohigashi, H.; Wender, P. A.; Miller B. L.; Takeda, N."Synthesis and Characterization of New Photolabile Phorbol Esters for Affinity Labeling of Protein Kinase C" J. Org. Chem. 1996, 61, 2164-2173. Abstract, PDF, Supporting Information
  • Wender, P. A.; Irie, K.; Miller, B. L."Identification, Activity, and Structural Studies of Peptides incorporating the Phorbol Ester-Binding Domain of Protein-Kinase-C" Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 239-243. Abstract, PDF
  • Irie, K.; Koizumi, F.; Iwata, Y.; Ishii, T.; Yanai, Y.; Nakamura, Y.; Ohigashi, H.; Wender, P. A. "Synthesis and Biological-Activities of New Conformationally Fixed Analogs of (-)-indolactam-V, the Core Structure of Tumor-Promoting Teleocidins" Bioorg. Med. Chem. Lett. 1995, 5, 453-458.
  • Wender, P. A.; Irie, K.; Miller, B. L. "Synthesis and Binding of Photoaffinity Ligand Candidates for Protein-Kinase-C" J. Org. Chem. 1993, 58, 4179-4181.
  • Wender, P. A.; Cribbs, C. M. "Structural Design in Anti-tumor Compounds." In Molecular Mechanisms and Their Clinical Applications in Malignancies; Bergsagel, Daniel E. and Mak, Tak W., Eds.; Academic ; San Diego, CA, 215, 1991.
  • Wender, P. A.; Cribbs, C. M. "Computer Assisted Molecular Design Related to the Protein Kinase C Receptor," In Advances in Medicinal Chemistry; Maryanoff, C.A., Maryanoff, B.E., Eds.; JAI; Greenwich, CT; 1, 1-53, 1992.
  • Wender, P. A. "Chemsitry, Computers, and Carcinogenesis" Pure Appl. Chem., 1989, 61, 469.
  • Wender, P. A.; Koehler, K. F.; Sharkey, N. A.; Dellaquila, M. L.; Blumberg, P. M. "Analysis of the Phorbol Ester Pharmacophore on Protein-Kinase-C As a Guide To the Rational Design of New Classes of Analogs" Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 4214-4218.
  • Wender, P. A.; Koehler, K.; Wilhelm, R.; Williams, P.; Keenan, R.; Lee, H. Y. "Tumor Promotion: Pharmacological and Synthetic Studies," in New Synthetic Methodology and Functionally Interesting Compounds, Z-I. Yoshida, Ed.; pp. 163-184, Elsevier Publishing Co., Amsterdam 1986.